Abstract: Sepsis still constitutes a common threat in inten-
Introduction
Sepsis is a life-threatening systemic body infection caused by microbial pathogens that if diagnosed in an early stage can be treated by the administration of antibiotics. The serum proteins CRP (C-reactive protein), PCT (Procalcitonin) and IL-6 (Interleukin 6) represent a reliable biomarker pool that can be exploited for the early and reliable diagnosis of sepsis. The serum proteins occur in clinically relevant ranges of 1 -500 µg/mL, 0.1 -50 ng/mL and 1 -1000 pg/mL respectively [1] . In the course of sepsis, Gram-positive and Gram-negative bacteria activate different inflammatory pathways that alter the cytokine profile [2] . To guide antibiotic treatment, early detection and identification of the causal microorganism class is of tremendous importance. Gram-negative and Gram-positive bacteria differ in their surface marker expression profile. The surface marker LPS (lipopolysaccharide) expressed by Gram-negative bacteria and LTA (lipoteichoic acid) expressed by Gram-positive bacteria can be exploited as specific marker for the fast Gram differentiation. So far, the standard procedure in the diagnosis of sepsis is based on the cultivation of blood samples and subsequent identification of the microorganisms. This method severely lacks of sensitivity and promptness and diagnosis demands for rapid and accurate point-of-care devices. Therefore, we developed a multiplexed protein microarray that allows the quantification of the sepsis-associated serum proteins and simultaneously allows the determination of the bacterial class of the causative pathogen. To meet the requirements of point-of-care devices and to provide a simple "one patient -one chip" device, we directly integrated the calibration on the chip. The large heterogeneity of the analytes regarding their concentrations requires a sandwich assay with low sensitivity for the quantification of CRP that occurs in rather high concentrations. CRP binds to phosphocholine with relatively low affinity (KD = 5 µM) [3] . The low affinity between CRP and phosphocholine is exploited for the development of a low-sensitive sandwich assay by immobilizing phosphocholine as capture molecule for CRP. In order to improve the overall assay sensitivity and the precision in the lower concentration ranges an enzymemediated signal amplification method that exploits the catalytic activity of the horse radish peroxidase (HRP) for turnover of multiple fluorophore labeled tyramide substrates to generate high density labeling is applied. Additionally, the chip allows the fast differentiation of the bacterial classes by the detection of the respective Gram specific surface marker. Surface imprinting techniques are applied to create nano-cavities in a polymer thin-film that coinstantaneously serves as substrate for the immobilization of the capture molecules. The surface imprinted nano-cavities are exploited as artificial capture antibodies in a sandwich immunoassay. We provide an accurate and fast point-of-care device that allows the simultaneous detection of the sepsis biomarker CRP, PCT and IL-6 that additionally allows the fast differentiation of bacterial classes by applying surface imprinting techniques.
Methods
A polymer thin-film is applied to glass slides that serves as substrate for surface imprinting of LTA and LPS and as substrate for the covalent immobilization of the capture antibodies for PCT and IL-6 or phosphocholine for CRP. The capture molecules necessary for the external calibration and the biotinylated detection antibodies exploited for the internal calibration are applied to the chip surface via contact spotting (NanoPrint, Arrayit). In order to create specific surface imprinted nano-cavities with high rebinding affinities for LPS or LTA, cover slips are inked with the respective analyte and pressed on the polymer thin-film. After curing, the stamps are removed and washed excessively to remove residual analytes. The so created nano-cavities as well as the spotted capture molecules are used for quantification of the respective analytes. For all analytes a sandwich assay is performed by the incubation of 25 µL serum diluted with 25 µL assay buffer and followed by the incubation of the biotinylated capture antibodies. Then, HRP conjugated to Streptavidin is incubated and the tyramide amplification is performed by the incubation of Alex Fluor 647 labeled tyramide that gets converted to a short-lived radical that binds to neighboured protein residues resulting in a localized high density labeling. Figure 2 shows the internal (green curves) and the external (black curves) calibration curves obtained for (a) IL-6, (b) PCT and (c) CRP. For all analytes the internal and the external curves match in terms of curve shape and maximal signal intensities. A coefficient of determination (R 2 ) of above 0.996 is obtained showing very strong correlations between the internal and external calibration. The significance is confirmed by a p-value below 0.0001 % for all 3 analytes. The curves match the clinically relevant ranges and LODs (limit of detection) of 4 pg/mL, 0.1 ng/mL and 1 µg/mL for IL-6, PCT and CRP respectively are reached. 
Results

Discussion
We developed a simple and fast diagnostic tool that allows the accurate and reliable diagnosis of sepsis. Through the application of the enzyme-mediated signal amplification step, the dynamic ranges of the assay strike the clinically relevant ranges of the serum biomarker CRP, PCT and IL-6. The key requirements of point-ofcare devices are met by the implementation of the calibration directly on the chip. The internal calibration reduces the effort of preparing an external standard dilution series. Additionally, specific surface imprints with high affinities for LPS or LTA that allow the fast differentiation of Gram-positive and Gram-negative bacteria are implemented on the chip.
